Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tak Yin Owen Tsang
Observed names:
T. Y. Tsang,
Tak Yin Tsang,
Tak-Yin Tsang,
Tak-yin Tsang
Institution:
Princess Margaret Hospital
Observed institutions:
Princess Margaret Cancer Centre,
Princess Margaret Hospital,
Princess Margaret Hospital,
Princess Margaret Hospital
OpenAlex ID:
A5024319613
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial
2016
·
Henry L Y Chan
, Scott Fung
, et al.
·
The Lancet. Gastroenterology & hepatology
·
469
SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases
2004
·
Tai-Nin Chau
, Kam-Cheong Lee
, et al.
·
Hepatology
·
424
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
2020
·
Susan A Olender
, Katherine K Perez
, et al.
·
Clinical Infectious Diseases
·
161
PDF
Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome
2004
·
Tai-nin Chau
, Po-oi Lee
, et al.
·
The American Journal of Medicine
·
38
PDF
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
2024
·
Harry L A Janssen
, Young-Suk Lim
, et al.
·
The Lancet. Gastroenterology & hepatology
·
16
Non-invasive screening of HLA-DPA1 and HLA-DPB1 alleles for persistent hepatitis B virus infection: Susceptibility for vertical transmission and toward a personalized approach for vaccination and treatment
2011
·
Kin-Chong Lau
, Ching-Wan Lam
, et al.
·
Clinica Chimica Acta
·
15
Epstein-Barr virus-associated smooth muscle tumor in patients with acquired immunodeficiency syndrome.
2007
·
Ka Hing Wong
, Kenny Chi-Wai Chan
, et al.
·
PubMed
·
11
First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong: Table 1.
2016
·
Wai Shing Leung
, Man Chun Chan
, et al.
·
Journal of Travel Medicine
·
9
PDF
Severe acute respiratory syndrome: clinical features
2005
·
Po Oi Lee
, Ping Tim Tsui
, et al.
·
Birkhäuser Basel eBooks
·
8
PDF
Kaposi sarcoma herpesvirus (KSHV) inflammatory cytokine syndrome (KICS): a case study
2025
·
Ming Hong Choi
, Ching See Leung
, et al.
·
BMC Infectious Diseases
·
7
PDF
Evaluation of in-house and commercial genotyping assays for molecular typing of hepatitis C virus in Hong Kong
2010
·
T. H. J. Lam
, P. S. Cheng
, et al.
·
British Journal of Biomedical Science
·
5
Use of high flow nasal cannula oxygen therapy for patients infected with SARS-CoV-2 outside intensive care setting
2023
·
Chak Kwan Tong
, Yu Hong Chan
, et al.
·
Journal of Thoracic Disease
·
4
PDF
Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study
2020
·
Young-Suk Lim
, Chun-yen Lin
, et al.
·
Journal of Hepatology
·
4
PDF
No increased risk of tuberculosis‐related immune reconstitution inflammatory syndrome with integrase inhibitor‐based antiretroviral therapy in people with HIV with profound immunosuppression
2024
·
Chi Kuen Chan
, Shan Shan Huang
, et al.
·
HIV Medicine
·
3
S1126 Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study
2020
·
Ho S. Bae
, Young-Suk Lim
, et al.
·
The American Journal of Gastroenterology
·
2
Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study
2020
·
Harry Janssen
, Pietro Lampertico
, et al.
·
Journal of Hepatology
·
2
PDF
A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results
2016
·
Henry Lik-Yuen Chan
, Scott Fung
, et al.
·
Clinical Gastroenterology and Hepatology
·
2
IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2
2021
·
Young-Suk Lim
, Chun-Yen Lin
, et al.
·
1
PDF
IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)
2021
·
Harry LA Janssen
, Pietro Lampertico
, et al.
PDF
O-13 : Switching from Tenofovir Disoproxil Fumarate (TDF) or Other Oral Antiviral Therapy (OAV) to Tenofovir Alafenamide (TAF) in Virally Suppressed CHB Patients with Hepatic Impairment
2020
·
Sang Hoon Ahn
, Pietro Lampertico
, et al.
·
춘·추계 학술대회 (KASL)
SAT-142-Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study
2019
·
Vincent Wai-Sun Wong
, Terry CF Yip
, et al.
·
Journal of Hepatology
IDDF2018-ABS-0106 Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies
2018
·
Henry Lik-Yuen Chan
, Wai Kay Seto
, et al.
PDF
Show more works
View as search
Works count:
22
Citation count:
1,181
H-index:
8
I10-index:
7
Year
Topic
Type
